TENX•benzinga•
Tenax Therapeutics AnnounceS FDA Review Completion Of Updated Phase 3 Plan For TNX-103, Expands LEVEL Study Enrollment To 230 Patients With Over 95% Power; LEVEL-2 Global Study To Begin In 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 5, 2025 by benzinga